{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T22:51:06Z","timestamp":1776639066599,"version":"3.51.2"},"reference-count":59,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Patients with essential thrombocythemia (ET) and coronary artery disease (CAD) have increased risk of thromboembolic complications. In addition, a reduced antiplatelet effect of aspirin has been demonstrated in both patient groups. As ET is a platelet disorder, platelets may be more important for the thromboembolic risk in ET than in CAD. We aimed to investigate the antiplatelet effect of aspirin and platelet turnover in ET versus CAD patients.<\/jats:p><jats:p>\n          Methods\u2003We included 48 ET patients and an age-matched group of 48 CAD patients. The effect of aspirin was evaluated by thromboxane B2 (TXB2) levels and platelet aggregation. Platelet turnover was assessed by immature platelet count (IPC) and immature platelet fraction (IPF).<\/jats:p><jats:p>\n          Results\u2003ET patients had reduced effect of aspirin compared with CAD patients, demonstrated by significantly higher TXB2 levels (median of differences\u2009=\u200922.3\u2009ng\/mL, p\u2009&lt;\u20090.0001) and platelet aggregation (median of differences\u2009=\u2009131.0 AU*min, p\u2009=\u20090.0003). Furthermore, ET patients had significantly higher IPC (p\u2009&lt;\u20090.0001) and IPF (p\u2009=\u20090.0004) than CAD patients.<\/jats:p><jats:p>\n          Conclusion\u2003ET patients have lower 24-hour antiplatelet effect of aspirin than CAD patients. This may be explained by an increased platelet production and turnover counteracting the antiplatelet effect of aspirin. These findings strengthen the rationale for exploring novel antiplatelet regimens in ET patients to reduce the risk of cardiovascular events.<\/jats:p>","DOI":"10.1055\/s-0041-1731309","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T22:30:22Z","timestamp":1625437822000},"page":"e230-e238","source":"Crossref","is-referenced-by-count":6,"title":["Lower Antiplatelet Effect of Aspirin in Essential Thrombocythemia than in Coronary Artery Disease"],"prefix":"10.1055","volume":"05","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-270X","authenticated-orcid":false,"given":"Oliver Buchhave","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Mette","family":"Hvas","sequence":"additional","affiliation":[{"name":"Thrombosis and Haemostasis Research Unit, Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Beier","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen Dalby","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-0865","authenticated-orcid":false,"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"A Tefferi","year":"2019","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"C Baigent","year":"2009","journal-title":"Lancet"},{"issue":"15","key":"ref3","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"S Pascale","year":"2012","journal-title":"Blood"},{"issue":"22","key":"ref4","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"A Carobbio","year":"2011","journal-title":"Blood"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"A Dragani","year":"2010","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"G Krasopoulos","year":"2008","journal-title":"BMJ"},{"issue":"15","key":"ref7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","article-title":"Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis","volume":"167","author":"J D Snoep","year":"2007","journal-title":"Arch Intern Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia","volume":"129","author":"J G Dillinger","year":"2012","journal-title":"Thromb Res"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood-2005-08-3526","article-title":"Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia","volume":"107","author":"A I Schafer","year":"2006","journal-title":"Blood"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","article-title":"Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome","volume":"68","author":"U Budde","year":"1986","journal-title":"Blood"},{"issue":"03","key":"ref11","first-page":"459","article-title":"Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing","volume":"114","author":"M K Freynhofer","year":"2015","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijcard.2014.05.013","article-title":"24-hour antiplatelet effect of aspirin in patients with previous definite stent thrombosis","volume":"175","author":"M W\u00fcrtz","year":"2014","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijcard.2010.02.025","article-title":"Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease","volume":"150","author":"M Lordkipanidz\u00e9","year":"2011","journal-title":"Int J Cardiol"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"B Rocca","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"A Tefferi","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-018-0078-3","article-title":"The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"V De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11239-013-0932-x","article-title":"Propensity for young reticulated platelet recruitment into arterial thrombi","volume":"37","author":"R D McBane II","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jacc.2008.05.031","article-title":"Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease","volume":"52","author":"S Guthikonda","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref19","first-page":"930","article-title":"Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy","volume":"99","author":"F Cesari","year":"2008","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1073\/pnas.112202999","article-title":"Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets","volume":"99","author":"B Rocca","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S HCE Swerdlow","year":"2017"},{"issue":"06","key":"ref22","first-page":"781","article-title":"Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood","volume":"96","author":"O T\u00f3th","year":"2006","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/09537104.2018.1430356","article-title":"Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis","volume":"30","author":"M L Larsen","year":"2019","journal-title":"Platelets"},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/eurheartj\/ehm232","article-title":"Laboratory detection of \u2018aspirin resistance\u2019: what test should we use (if any)?","volume":"28","author":"M Cattaneo","year":"2007","journal-title":"Eur Heart J"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1538-7836.2008.03184.x","article-title":"Aspirin \u2018resistance\u2019: role of pre-existent platelet reactivity and correlation between tests","volume":"6","author":"A L Frelinger","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2011.08.019","article-title":"Platelet aggregation is dependent on platelet count in patients with coronary artery disease","volume":"129","author":"M W\u00fcrtz","year":"2012","journal-title":"Thromb Res"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/cyto.b.21642","article-title":"Platelet characteristics in patients with essential thrombocytosis","volume":"94","author":"O H Pedersen","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/2047-783X-15-5-214","article-title":"Impact of platelet count on results obtained from multiple electrode platelet aggregometry (Multiplate)","volume":"15","author":"A A Hanke","year":"2010","journal-title":"Eur J Med Res"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1111\/jth.12432","article-title":"Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate\u2122 analyzer) and with light transmission aggregometry","volume":"11","author":"E A Femia","year":"2013","journal-title":"J Thromb Haemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2018.05.009","article-title":"Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count","volume":"200","author":"T Gremmel","year":"2018","journal-title":"Transl Res"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bcmd.2005.12.031","article-title":"Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles","volume":"36","author":"P E Petrides","year":"2006","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1055\/s-0040-1714351","article-title":"Patients with essential thrombocythemia may be poor responders to enteric-coated aspirin, but not to plain aspirin","volume":"120","author":"M Scavone","year":"2020","journal-title":"Thromb Haemost"},{"issue":"22","key":"ref33","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"C Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"K Schr\u00f6r","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/cpt.694","article-title":"In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease","volume":"102","author":"A Giaretta","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"J W Burch","year":"1978","journal-title":"J Clin Invest"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"F Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2012-10-429134","article-title":"Platelet activation and inhibition in polycythemia vera and essential thrombocythemia","volume":"121","author":"C Patrono","year":"2013","journal-title":"Blood"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1160\/TH05-10-0653","article-title":"Dose- and time-dependent antiplatelet effects of aspirin","volume":"95","author":"C Perneby","year":"2006","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"B Rocca","year":"2020","journal-title":"Blood"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-2006-939436","article-title":"Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies","volume":"32","author":"R Landolfi","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7326\/M17-0284","article-title":"Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review","volume":"167","author":"D K Chu","year":"2017","journal-title":"Ann Intern Med"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"A Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"08","key":"ref44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"V De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5492\/wjccm.v4.i3.230","article-title":"Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients","volume":"4","author":"J J Michiels","year":"2015","journal-title":"World J Crit Care Med"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01698487","article-title":"Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count","volume":"69","author":"P J van Genderen","year":"1994","journal-title":"Ann Hematol"},{"issue":"02","key":"ref48","first-page":"67","article-title":"Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera","volume":"15","author":"J J Michiels","year":"2004","journal-title":"Platelets"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-8652(199601)51:1<79::AID-AJH13>3.0.CO;2-6","article-title":"Platelet activation and thrombosis: studies in a patient with essential thrombocythemia","volume":"51","author":"P Nurden","year":"1996","journal-title":"Am J Hematol"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2013.05.003","article-title":"ADP-induced platelet aggregation and thrombin generation are increased in essential thrombocythemia and polycythemia vera","volume":"132","author":"M Panova-Noeva","year":"2013","journal-title":"Thromb Res"},{"issue":"08","key":"ref51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jcin.2010.05.014","article-title":"Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets","volume":"3","author":"M W\u00fcrtz","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1538-7836.2007.02387.x","article-title":"Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin","volume":"5","author":"S Guthikonda","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2016.04.056","article-title":"Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy","volume":"68","author":"C Stratz","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref54","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1538-7836.2011.04304.x","article-title":"Increased platelet turnover in patients with previous definite stent thrombosis","volume":"9","author":"E L Grove","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ajh.21338","article-title":"Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden","volume":"84","author":"E Arellano-Rodrigo","year":"2009","journal-title":"Am J Hematol"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood.V91.4.1288","article-title":"Correlation of thrombosis with increased platelet turnover in thrombocytosis","volume":"91","author":"H M Rinder","year":"1998","journal-title":"Blood"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12265-013-9534-4","article-title":"Gender and anti-thrombotic therapy: from biology to clinical implications","volume":"7","author":"R Marcucci","year":"2014","journal-title":"J Cardiovasc Transl Res"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.thromres.2012.06.017","article-title":"Reference intervals for platelet aggregation assessed by multiple electrode platelet aggregometry","volume":"130","author":"P Rubak","year":"2012","journal-title":"Thromb Res"},{"issue":"11","key":"ref59","first-page":"549","article-title":"Cigarette smoking and platelet aggregation","volume":"95","author":"M F Glynn","year":"1966","journal-title":"Can Med Assoc J"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1731309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T13:35:55Z","timestamp":1627911355000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1731309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":59,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2021,7,4]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1731309","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}